Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pyrimidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL20958 | 0.89 | ALDH1A1 (0.58) | MAPTALDH1A1LMNASMN1; SMN2KDM4E | |
| Pyridine SCHEMBL31483849 | 0.89 | ALDH1A1 (0.58) | MAPTALDH1A1LMNASMN1; SMN2KDM4E | |
| Pyridine SCHEMBL2126952 | 0.89 | ALDH1A1 (0.58) | MAPTALDH1A1LMNASMN1; SMN2KDM4E | |
| Pyridine SCHEMBL7656088 | 0.89 | ALDH1A1 (0.58) | MAPTALDH1A1LMNASMN1; SMN2KDM4E | |
| Pyridine SCHEMBL3261023 | 0.89 | ALDH1A1 (0.58) | MAPTALDH1A1LMNASMN1; SMN2KDM4E | |
| Pyridine SCHEMBL6427981 | 0.89 | ALDH1A1 (0.58) | MAPTALDH1A1LMNASMN1; SMN2KDM4E | |
| Pyridine SCHEMBL28538739 | 0.87 | ALDH1A1 (0.57) | MAPTALDH1A1LMNASMN1; SMN2KDM4E | |
| Pyridine SCHEMBL28299965 | 0.87 | ALDH1A1 (0.57) | MAPTALDH1A1LMNASMN1; SMN2KDM4E | |
| Pyridine SCHEMBL5968326 | 0.87 | ALDH1A1 (0.57) | MAPTALDH1A1LMNASMN1; SMN2KDM4E | |
| Pyridine SCHEMBL28981792 | 0.87 | ALDH1A1 (0.57) | MAPTALDH1A1LMNASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | disclosed |
| CN-117836304-A | Improved oligonucleotide synthesis | 巴克姆股份公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-113286778-B | Ubiquitin analogs | MMV疟疾药物投资公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-113286778-A | Panamide analogs | MMV疟疾药物投资公司 | 2021-08-20 | — | — | CN | disclosed |
| CN-105073699-B | Compounds containing structural units derived from vinyl ether compounds | 东京应化工业株式会社 | 2019-10-25 | — | — | CN | disclosed |
| EP-2457923-B1 | STEROL DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20150119585-A1 | STEROL DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2015-04-30 | — | — | US | disclosed |
| US-8952003-B2 | Sterol derivative | KYOWA HAKKO KIRIN CO., LTD (JP) | 2015-02-10 | — | — | US | disclosed |
| CN-101778851-B | Fused bicyclic pyrimidines | BAYER SCHERING PHARMA AG | 2013-05-08 | — | — | CN | disclosed |
| CN-102781462-A | Novel nucleoside phosphonates and analogs | EPIPHANY BIOSCIENCES INC | 2012-11-14 | — | — | CN | disclosed |
| CN-1468214-A | Novel derivatives of aminocyclohexane | - | 2004-01-14 | — | — | CN | disclosed |
| US-20030186984-A1 | Substituted cyclohexane derivatives | HOFFMAN-LA ROCHE INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003053933-A1 | HETEROARYL-SUBSTITUTED AMINOCYCLOHEXANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-07-03 | — | — | WO | disclosed |
| EP-1317432-A1 | PIPERIDINE DERIVATIVES FOR USE AS 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-11 | — | — | EP | disclosed |
| EP-1311475-A1 | NOVEL AMINOCYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-21 | — | — | EP | disclosed |
| US-20020068753-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. | 2002-06-06 | — | — | US | disclosed |
| US-20020045777-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | disclosed |
| WO-2002020483-A1 | PIPERIDINE DERIVATIVES FOR USE 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002014267-A1 | NOVEL AMINOCYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-21 | — | — | WO | disclosed |
| US-5053507-A | Liquid crystal dopants | ARAKAWA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1991-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186984-A1 | Substituted cyclohexane derivatives | CYP51A1, LSS, CYP46A1 | EGFR 4775/4885MAPT 4716/4885ALDH1A1 414/4885 |
| US-20150119585-A1 | STEROL DERIVATIVE | NR1H3, NR1H2, SREBF1 | EGFR 2460/4885MAPT 3023/4885ALDH1A1 1621/4885 |
| US-20020068753-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | EGFR 4467/4885MAPT 4409/4885ALDH1A1 1343/4885 |
| US-20020045777-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | EGFR 4142/4885MAPT 4081/4885ALDH1A1 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.